Epidemiology of hyperkalemia in CKD patients under nephrological care: a longitudinal study.
ACE inibitors
Acidosis
Angiotensin II receptor blockers
Chronic kidney disease
Hyperkalemia
Longitudinal study
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
14
09
2020
accepted:
22
01
2021
pubmed:
13
2
2021
medline:
23
11
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
Hyperkalemia is a potential life-threatening condition among chronic kidney disease (CKD) patients. Available estimates of the burden of this alteration in CKD are mainly derived from large administrative databases. Since K measurements in patients in these databases are often dictated by clinical reasons, longitudinal studies including pre-planned measurements of potassium independently of clinical complication/symptoms may produce more reliable estimates of the frequency and the risk factors underlying hyperkalemia in CKD patients. We estimated the prevalence and the incidence of hyperkalemia in a longitudinal study in 752 stages 2-5 CKD patients lasting 3 years and including up to seven pre-planned assessment of key biochemical measurements including K. At baseline, 203 out of 752 patients (27%) had serum K > 5.0 mM/L and 33% had acidosis (HCO
Identifiants
pubmed: 33575905
doi: 10.1007/s11739-021-02653-8
pii: 10.1007/s11739-021-02653-8
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1803-1811Informations de copyright
© 2021. Società Italiana di Medicina Interna (SIMI).
Références
Palmer BF, Clegg DJ (2017) Treatment of abnormalities of potassium homeostasis in CKD. Adv Chronic Kidney Dis 24:319–324. https://doi.org/10.1053/j.ackd.2017.06.001
doi: 10.1053/j.ackd.2017.06.001
pubmed: 29031359
Gilligan S, Raphael KL (2017) Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes. Adv Chronic Kidney Dis 24:315–318. https://doi.org/10.1053/j.ackd.2017.06.004
doi: 10.1053/j.ackd.2017.06.004
pubmed: 29031358
Kovesdy CP (2016) Epidemiology of hyperkalemia: an update. Kidney IntSuppl 6:3–6. https://doi.org/10.1016/j.kisu.2016.01.002
doi: 10.1016/j.kisu.2016.01.002
Luo J, Brunelli SM, Jensen DE, Yang A (2016) Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am SocNephrol 11:90–100. https://doi.org/10.2215/CJN.01730215
doi: 10.2215/CJN.01730215
Thomsen RW, Nicolaisen SK, Hasvold P et al (2018) Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes—a Danish population-based cohort study. Nephrol Dial Transplant 33:1610–1620. https://doi.org/10.1093/ndt/gfx312
doi: 10.1093/ndt/gfx312
pubmed: 29177463
Gasparini A, Evans M, Barany P et al (2019) Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project. Nephrol Dial Transplant 34:1534–1541. https://doi.org/10.1093/ndt/gfy249
doi: 10.1093/ndt/gfy249
pubmed: 30085251
Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W et al (2017) Impact of admission serum potassium on mortality in patients with chronic kidney disease and cardiovascular disease. QJM AnInt J Med 110:713–719. https://doi.org/10.1093/qjmed/hcx118
doi: 10.1093/qjmed/hcx118
Weiner ID, Wingo CS (1998) Hyperkalemia: a potential silent killer. J Am SocNephrol 9:1535–1543
Perazella MA (2000) Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 109:307–314. https://doi.org/10.1016/S0002-9343(00)00496-4
doi: 10.1016/S0002-9343(00)00496-4
pubmed: 10996582
Allon M (2014) Disorders of potassium metabolism. In: Gilbert SJ, Daniel E (eds) National Kidney foundation primer on kidney diseases, 6th edn. Weiner Elsevier, pp 90–99
Palmer BF (2020) Potassium binders for hyperkalemia in chronic kidney disease—diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis. Mayo ClinProc 95:339–354. https://doi.org/10.1016/j.mayocp.2019.05.019
doi: 10.1016/j.mayocp.2019.05.019
Collins AJ, Pitt B, Reaven N et al (2017) Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol 46:213–221. https://doi.org/10.1159/000479802
doi: 10.1159/000479802
pubmed: 28866674
Einhorn LM, Zhan M, Hsu VD et al (2009) The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169:1156. https://doi.org/10.1001/archinternmed.2009.132
doi: 10.1001/archinternmed.2009.132
pubmed: 19546417
pmcid: 3544306
Epstein M (2016) Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney IntSuppl 6:20–28. https://doi.org/10.1016/j.kisu.2016.01.004
doi: 10.1016/j.kisu.2016.01.004
Levin A, Stevens PE, Bilous RW et al (2013) Notice. Kidney IntSuppl 3:1. https://doi.org/10.1038/kisup.2012.73
doi: 10.1038/kisup.2012.73
James PA, Oparil S, Carter BL et al (2014) 2014 Evidence-based guideline for the management of high blood pressure in adults. JAMA 311:507. https://doi.org/10.1001/jama.2013.284427
doi: 10.1001/jama.2013.284427
pubmed: 24352797
Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Am CollCardiol 70:776–803. https://doi.org/10.1016/j.jacc.2017.04.025
doi: 10.1016/j.jacc.2017.04.025
(2019) 10. Cardiovascular disease and risk management: Standards of medical care in diabetes 2019. Diabetes Care. https://doi.org/10.2337/dc19S010
Chang AR, Sang Y, Leddy J et al (2016) Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension 67:1181–1188. https://doi.org/10.1161/HYPERTENSIONAHA.116.07363
doi: 10.1161/HYPERTENSIONAHA.116.07363
pubmed: 27067721
Hu J-R, Coresh J (2017) The public health dimension of chronic kidney disease: what we have learnt over the past decade. Nephrol Dial Transplant 32:i1113–i1120. https://doi.org/10.1093/ndt/gfw416
doi: 10.1093/ndt/gfw416
Lazich I, Bakris GL (2014) Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. SeminNephrol 34:333–339. https://doi.org/10.1016/j.semnephrol.2014.04.008
doi: 10.1016/j.semnephrol.2014.04.008
Latts LM, Reaven NL, Funk SE et al (2015) Hyperkalemia Is highly prevalent in patients with cardiorenal comorbidities compared to patients without these comorbidities. Value Heal 18:A135. https://doi.org/10.1016/j.jval.2015.03.786
doi: 10.1016/j.jval.2015.03.786
Kashihara N, Kohsaka S, Kanda E et al (2019) Hyperkalemia in real-world patients under continuous medical care in Japan. Kidney Int Reports 4:1248–1260. https://doi.org/10.1016/j.ekir.2019.05.018
doi: 10.1016/j.ekir.2019.05.018
Sarafidis PA, Blacklock R, Wood E et al (2012) Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am SocNephrol 7:1234–1241. https://doi.org/10.2215/CJN.01150112
doi: 10.2215/CJN.01150112
Hayes J, Kalantar-Zadeh K, Lu JL et al (2012) Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron ClinPract 120:c8–c16. https://doi.org/10.1159/000329511
doi: 10.1159/000329511
Zoccali C, Leonardis D, Enia G et al (2008) The MAURO study: multiple intervention and audit in renal diseases to optimize care. J Nephrol 21:20–22
pubmed: 18264932
Leonardis D, Mallamaci F, Enia G et al (2012) The MAURO study: Baseline characteristics and compliance with guidelines targets. J Nephrol 25:1081–1090
doi: 10.5301/jn.5000239
Levey AS (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461. https://doi.org/10.7326/0003-4819-130-6-199903160-00002
doi: 10.7326/0003-4819-130-6-199903160-00002
Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, Ariyanayagam R, Al-Yassin A, Sharpe C, Vinen K (2012) Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am SocNephrol 8:1234–1241
doi: 10.2215/CJN.01150112
Hanley JA, Negassa A, de Edwardes MDB, Forrester JE (2003) Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 157:364–375. https://doi.org/10.1093/aje/kwf215
doi: 10.1093/aje/kwf215
pubmed: 12578807
Bianchi S, Aucella F, De Nicola L et al (2019) Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol 32:499–516. https://doi.org/10.1007/s40620-019-00617-y
doi: 10.1007/s40620-019-00617-y
pubmed: 31119681
pmcid: 6588653
Provenzano M, Minutolo R, Chiodini P, Bellizzi V, Nappi F, Russo D, Borrelli S, Garofalo C, Iodice C, De Stefano T, Conte G, Heerspink HJL, De Nicola L (2018) Competing-risk analysis of death and end stage kidney disease by hyperkalaemia status in non-dialysis chronic kidney disease patients receiving stable nephrology care. J Clin Med 7:499. https://doi.org/10.3390/jcm7120499
doi: 10.3390/jcm7120499
pmcid: 6306758
Sousa AGP, de Cabral JVS, El-Feghaly WB et al (2016) Hyporeninemichypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management. World J Diabetes 7:101. https://doi.org/10.4239/wjd.v7.i5.101
doi: 10.4239/wjd.v7.i5.101
pubmed: 26981183
pmcid: 4781902
Chatterjee R, Yeh H-C, Edelman D, Brancati F (2011) Potassium and risk of type 2 diabetes. Expert Rev EndocrinolMetab 6:665–672. https://doi.org/10.1586/eem.11.60
doi: 10.1586/eem.11.60
Ben Salem C, Badreddine A, Fathallah N et al (2014) Drug-induced hyperkalemia. Drug Saf 37:677–692. https://doi.org/10.1007/s40264-014-0196-1
doi: 10.1007/s40264-014-0196-1
pubmed: 25047526
Burnell JM, Villamil MF, Uyeno BT, Scribner BH (1956) The effect in humans of extracellular pH change on the relationship between serum potassium concentration and intracellular potassium. J Clin Invest 35:935–939. https://doi.org/10.1172/JCI103352
doi: 10.1172/JCI103352
pubmed: 13367188
pmcid: 441665